趨化因子配體2(CXCL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Chemokine (C-X-C Motif) Ligand 2 (CXCL2) ,etc. by FLIA (Flow Luminescence Immunoassay)
GROb; SCYB2; MIP2; GRO2; MIP2a; MGSAb; CINC2a; HSF; Macrophage inflammatory protein 2-alpha; Hematopoietic synergistic factor; Growth Regulated Oncogene Beta
(注:?jiǎn)未位鞙y(cè)多因子不超過8個(gè)指標(biāo) )
- 編號(hào)LMB603Ra
- 物種Rattus norvegicus (Rat,大鼠) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.98-1000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.327 pg/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2090 ¥ 2171 ¥ 2291 ¥ 2452 ¥ 2613 ¥ 2854 ¥ 3216 計(jì)算器 ¥ 4020 添加到價(jià)格計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)趨化因子配體2(CXCL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的趨化因子配體2(CXCL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 92-99 | 96 |
EDTA plasma(n=5) | 96-104 | 101 |
heparin plasma(n=5) | 80-95 | 80 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的趨化因子配體2(CXCL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中趨化因子配體2(CXCL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 82-94% | 88-97% | 82-91% | 83-97% |
EDTA plasma(n=5) | 92-103% | 83-105% | 97-105% | 92-99% |
heparin plasma(n=5) | 87-103% | 78-96% | 91-99% | 83-102% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測(cè)溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測(cè)溶液B100μL,37°C振動(dòng)孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將趨化因子配體2(CXCL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的趨化因子配體2(CXCL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的趨化因子配體2(CXCL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的趨化因子配體2(CXCL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Rattus norvegicus (Rat,大鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
APB603Ra01 | 趨化因子配體2(CXCL2)活性蛋白 | Cell?culture;?Activity?Assays. |
RPB603Ra01 | 趨化因子配體2(CXCL2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB603Ra01 | 趨化因子配體2(CXCL2)多克隆抗體 | WB; IHC; ICC; IP. |
MAB603Ra21 | 趨化因子配體2(CXCL2)單克隆抗體 | WB; IHC; ICC; IP. |
SEB603Ra | 趨化因子配體2(CXCL2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB603Ra | 趨化因子配體2(CXCL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
FEBS Journal | Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B [PubMed: 19120450] |
PLoS One. | HIF-1α Is Essential for Effective PMN Bacterial Killing, Antimicrobial Peptide Production and Apoptosis in Pseudomonas aeruginosa Keratitis [Plos: Source] |
Physiol Genomics. | Identification of human exercise-induced myokines using secretome analysis [Pubmed:24520153] |
Diabetes | Protein Inhibitor of Activated STAT 1 (PIAS1) Protects Against Obesity-Induced Insulin Resistance by Inhibiting Inflammation Cascade in Adipose Tissue [PubMed: 26324179] |
Respiration | Bubble CPAP support after discontinuation of mechanical ventilation protects rat lungs with ventilator-induced lung injury [Pubmed:26800273] |
Scientific Reports | The Transcriptional Foundations of Sp110-mediated Macrophage (RAW264. 7) Resistance to Mycobacterium tuberculosis H37Ra [Pubmed:26912204] |
Cellular Physiology and Biochemistry | Dexmedetomidine Alleviates HyperoxiaInduced Acute Lung Injury via Inhibiting NLRP3 Inflammasome Activation [pubmed:28873369] |
Medicine (Baltimore) | Rapid detection of urinary soluble intercellular adhesion molecule-1 for determination of lupus nephritis activity [Pubmed:29953010] |
Hepatology | Integrated Omics Reveals Tollip as an Aggravator and Therapeutic Target for Hepatic Ischemia‐Reperfusion Injury in Mice [Pubmed: 31077413] |
Molecular Medicine Reports | IL?17A promotes CXCR2?dependent angiogenesis in a mouse model of liver cancer [Pubmed: 31173199] |
Anticancer Research | The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer [Pubmed: 31810929] |
Lab Invest | Extracellular cold-inducible RNA-binding protein regulates neutrophil extracellular trap formation and tissue damage in acute pancreatitis [Pubmed: 32709888] |
SCIENCE OF THE TOTAL ENVIRONMENT | Assessment of acute toxicological effects of molybdenum (IV) disulfide nano-and microparticles after single intratracheal administration in rats [Pubmed: 32629262] |
Autophagy | Vitamin D3 and carbamazepine protect against Clostridioides difficile infection in mice by restoring macrophage lysosome acidification [Pubmed:34989311] |